Analyst firms · Raymond James · VRTX

Raymond James VRTX price target and rating history

Vertex Pharmaceuticals Incorporated (VRTX) · Health Care

Raymond James rates Vertex Pharmaceuticals Incorporated (VRTX) Mkt Perform, as of its latest action on Sep 3, 2025. It has published 3 rating actions on VRTX since July 2021, including 0 upgrades and 0 downgrades. Across 10 firms with a VRTX price target in the last 12 months, the median target is $577.50.

Current rating
Mkt Perform
Price target
Not stated
Median target, all firms
$577.50
Actions on VRTX
3

Every Raymond James rating on VRTX

How other firms rate VRTX

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Leerink PartnersOutperform$594Sep 21, 2026
Morgan StanleyOverweight$665Sep 2, 2026
Truist SecuritiesBuy$542May 27, 2026
Maxim GroupBuy$575Mar 18, 2026
JefferiesBuy$580Mar 10, 2026
OppenheimerOutperform$600Mar 10, 2026
BarclaysOverweight$606Jan 28, 2026
RBC Capital MarketsOutperform$546Jan 22, 2026
BernsteinOutperformJan 12, 2026
UBSBuy$535Jan 7, 2026
Wolfe ResearchOutperform$548Jan 6, 2026

Questions about Raymond James and VRTX

What is Raymond James's rating on VRTX?
Raymond James rates VRTX Mkt Perform, a neutral rating, as of Sep 3, 2025.
When did Raymond James last change its view on VRTX?
On Sep 3, 2025, Raymond James starts coverage at Mkt Perform.
How does Raymond James's VRTX target compare with other analysts?
Across 10 firms with a VRTX price target in the last 12 months, the median target is $577.50.

More VRTX rating histories

All Raymond James ratingsVRTX news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.